Skip to content

PSYNAPSE

Active
Private limited companyfounded 2022active for 3 yearsRue de Nivelles 9, 1330 Rixensart, BelgiumKBO/BCE: BE 0793.500.778
Summary

PSYNAPSE has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €148,360 and a net result of €83,564. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 42% of 3,019 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Activity
Specialist medical practice
NACE 86220
1 site
Size
≈ €300,000turnover 2025, estimated
Equity
€148,360
Profit
€83,564
Turnover estimated from the gross margin
Financial health
91 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Structure
2025 accounts filed 61 days late
Why 91raises riskLast filed accounts filed 61 days late; 2 of the last 3 latelowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 1.59, cash €116,917Founded in 2022Show the evidence

Checked score

Score 2025
91 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 31% of its sector peers (NACE 86, micro)
Financial strength · tick = 2024
Strong
Solvency 74-26
equity 49.3% of total assets
Liquidity 73+8
short-term debt 50.7% · cash 38.9%
Profitability 76-24
return on assets 27.8%
Bankruptcy probability, 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,138 companies, NACE 86, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024lowest value 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: 0.1%▲ +0.1 percentage points vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.2%▲ +0.1 percentage points vs 08-2026highest value 10-2026: < 0.1%▼ -0.2 percentage points vs 09-2026
Credit of up to €13,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.59, compared with 21.98 in 2024, above the usual 1.5; short-term debt: 50.7% and cash: 38.9% of total assets), but 50.7% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 39% on solvency, 54% on liquidity, 20% on profitability and 11% on growth.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises risk
lowers risk · Sector: Human health activities (NACE 86)
KBO
raises risk · Last filed accounts filed 61 days late; 2 of the last 3 late
NBB · filings
lowers risk · Liquidity: current ratio 1.59, cash €116,917
NBB · annual accounts
lowers risk · Founded in 2022
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
raises risk · 2025 accounts filed 61 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-09-2026, 61 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 4 filings
Deviation from the deadline
2025
61 days late
2024
27 days late
2023
61 days late
2022
17 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 4 accounts on average 42 days after the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 13 September (4 of the last 4 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
29-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2022.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · full…
  3. Liquidity more than 5 timescurrent ratio 21.98

Financials · financial year 2025, abbreviated format

2025 annual accounts filed late (61 days) Filed on 30 September 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00544725.

Turnover
≈ €300,000
Estimated: probably between €250,000 and €400,000
EBIT margin
Not included in this filing
Net result
€83,564▼ 35.4%
2024 · €129,427
Working capital
€89,860▼ 68.5%
2024 · €285,284
Trend over the years

2022 to 2025, 4 financial years

The operating result has fallen two years in a row; 2025 is 10% below 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result€150,022 2025 Net result€83,564 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).

Every figure with its change against the financial year before
favourable unfavourable
Line2022202320242025
Operating result€81,838-€206,014▲ 152%€165,871▼ 19.5%€150,022▼ 9.6%
Net result€65,168within the sector's middle half-€157,889within the sector's middle half▲ 142%€129,427within the sector's middle half▼ 18.0%€83,564within the sector's middle half▼ 35.4%
Equity€67,168below the sector's middle half-€225,057within the sector's middle half▲ 235%€354,484within the sector's middle half▲ 57.5%€148,360within the sector's middle half▼ 58.1%
Total assets€109,061below the sector's middle half-€271,489below the sector's middle half▲ 149%€368,084within the sector's middle half▲ 35.6%€300,833below the sector's middle half▼ 18.3%
Debt€41,894-€46,432▲ 10.8%€13,600▼ 70.7%€152,474▲ 11×
Working capital-€26,832below the sector's middle half-€143,457within the sector's middle half€285,284within the sector's middle half▲ 98.9%€89,860within the sector's middle half▼ 68.5%
Solvency61.6%within the sector's middle half-82.9%above the sector's middle half▲ 21.3pp96.3%above the sector's middle half▲ 13.4pp49.3%within the sector's middle half▼ 47.0pp
Current ratio0.36below the sector's middle half-4.09within the sector's middle half▲ 3.7321.98above the sector's middle half▲ 17.891.59within the sector's middle half▼ 20.39
Return on assets (ROA)59.8%above the sector's middle half-58.2%above the sector's middle half▼ 1.6pp35.2%above the sector's middle half▼ 23.0pp27.8%above the sector's middle half▼ 7.4pp
above within below the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €300,833
Fixed assets €58,500 ▼ 15.5%
Current assets €242,333 ▼ 18.9%
Equity and liabilities €300,833
Equity €148,360 ▼ 58.1%
Debt €152,474 ▲ 11×
Debt's share of the balance-sheet total rises from 3.7% to 50.7%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€160,722▼
2024 · €178,271
Cash flow
€94,264▼
2024 · €141,827
Debt to equity
1.03▲
2024 · 0.04
ROE
56.3%▲
2024 · 36.5%
Interest coverage
3.07▼
2024 · over 100
Debt ≤ 1 year
€152,474▲
2024 · €13,600
Income taxes
€22,130▼
2024 · €38,505
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 39,278 companies that looked in July 2024 the way this one looks now, 1.8% went bankrupt within 24 months and 95.9% are still going.

  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
1.8% went bankrupt
2.3% stopped otherwise
95.9% still going

For this company itself Checked computes a lower bankruptcy probability: < 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 39,278 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 38 lines
Balance sheet Code20242025
Assets
Total assets20/58€368,084€300,833▼
Fixed assets21/28€69,200€58,500▼
Intangible fixed assets21€67,500€58,500▼
Tangible fixed assets22/27€1,700-
Furniture and vehicles24€1,700-
Current assets29/58€298,884€242,333▼
Amounts receivable within one year40/41€255,291€124,697▼
Trade receivables40€110,901€101,950▼
Other amounts receivable41€144,390€22,747▼
Cash at bank and in hand54/58€42,938€116,917▲
Deferred charges and accrued income490/1€655€719▲
Equity and liabilities
Total equity and liabilities10/49€368,084€300,833▼
Equity10/15€354,484€148,360▼
Contributions10/11€2,000€2,000=
Profit (loss) carried forward14€352,484€146,360▼
Amounts payable17/49€13,600€152,474▲
Amounts payable within one year42/48€13,600€152,474▲
Trade debts44-€330
Suppliers440/4-€330
Taxes, remuneration and social security45€13,600€52,144▲
Taxes450/3€13,600€52,144▲
Other amounts payable47/48-€100,000
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€12,400€10,700▼
Other operating charges640/8-€400
Gross operating margin9900€178,271€161,122▼
Operating profit (loss)9901€165,871€150,022▼
Financial income75/76B€2,123€8,094▲
Recurring financial income75€2,123€8,094▲
Financial charges65/66B€62€52,422▲
Recurring financial charges65€62€52,422▲
Profit (loss) for the period before taxes9903€167,932€105,694▼
Income taxes67/77€38,505€22,130▼
Profit (loss) for the period9904€129,427€83,564▼
Profit (loss) for the period to be appropriated9905€129,427€83,564▼
Appropriation of the result
Profit (loss) to be appropriated9906€352,484€436,048▲
Profit (loss) brought forward from the previous period14P€223,057€352,484▲
Profit to be distributed694/7-€289,688
Return on contributions (dividend)694-€289,688

The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2022202320242025Change
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€6,200€12,400€12,400€10,700▼ 13.7%
Other operating charges640/8---€400-
Gross operating margin9900€88,038€218,414€178,271€161,122▼ 9.6%
Operating profit (loss)9901€81,838€206,014€165,871€150,022▼ 9.6%
Financial income75/76B-€0€2,123€8,094▲ 281%
Recurring financial income75-€0€2,123€8,094▲ 281%
Financial charges65/66B€41€554€62€52,422▲ 846×
Recurring financial charges65€41€554€62€52,422▲ 846×
Profit (loss) for the period before taxes9903€81,798€205,460€167,932€105,694▼ 37.1%
Income taxes67/77€16,630€47,571€38,505€22,130▼ 42.5%
Profit (loss) for the period9904€65,168€157,889€129,427€83,564▼ 35.4%
Profit (loss) for the period to be appropriated9905€65,168€157,889€129,427€83,564▼ 35.4%
Line2022202320242025Change
Assets
Total assets20/58€109,061€271,489€368,084€300,833▼ 18.3%
Fixed assets21/28€94,000€81,600€69,200€58,500▼ 15.5%
Intangible fixed assets21€85,500€76,500€67,500€58,500▼ 13.3%
Tangible fixed assets22/27€8,500€5,100€1,700--
Furniture and vehicles24€8,500€5,100€1,700--
Current assets29/58€15,061€189,889€298,884€242,333▼ 18.9%
Amounts receivable within one year40/41€13,731€65,400€255,291€124,697▼ 51.2%
Trade receivables40€13,731€65,400€110,901€101,950▼ 8.1%
Other amounts receivable41--€144,390€22,747▼ 84.2%
Cash at bank and in hand54/58€939€123,714€42,938€116,917▲ 172%
Deferred charges and accrued income490/1€391€775€655€719▲ 9.8%
Equity and liabilities
Total equity and liabilities10/49€109,061€271,489€368,084€300,833▼ 18.3%
Equity10/15€67,168€225,057€354,484€148,360▼ 58.1%
Contributions10/11€2,000€2,000€2,000€2,000=
Profit (loss) carried forward14€65,168€223,057€352,484€146,360▼ 58.5%
Amounts payable17/49€41,894€46,432€13,600€152,474▲ 11×
Amounts payable within one year42/48€41,894€46,432€13,600€152,474▲ 11×
Trade debts44€1,840€122-€330-
Suppliers440/4€1,840€122-€330-
Taxes, remuneration and social security45€16,630€45,570€13,600€52,144▲ 283%
Taxes450/3€16,630€45,570€13,600€52,144▲ 283%
Other amounts payable47/48€23,424€740-€100,000-
Line2022202320242025Change
Profit (loss) for the period9904€65,168€157,889€129,427€83,564▼ 35.4%
+ Depreciation and write-downs630€6,200€12,400€12,400€10,700▼ 13.7%
Operating cash flow (approximation)€71,368€170,289€141,827€94,264▼ 33.5%
Investment in fixed assets (approximation)-€0€0€0-
Change in cash-€122,775-€80,776€73,979-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (4)
Financial year Type Filed Reference
31-12-2025 abbreviated format 30-09-2026 2026-00544725
31-12-2024 full format 27-08-2025 2025-00431813
31-12-2023 full format 30-09-2024 2024-00486672
31-12-2022 full format 17-08-2023 2023-00331403

Similar companies · same sector, comparable size

Of the 16,579 active companies whose main activity is specialist medical practice (NACE 86220), figures are known for 8,122. 6,814 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
1 director, no change since 2022
DEMONT Camille Ange-Marie
Director (not named in the articles) · since 16-11-2022
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

1 person since 2022, 1 in office
Show
  • Board
Mandates per person, with start and end dates
Name Functions and periods
DEMONT Camille Ange-Marie
  • Director (not named in the articles), from 16-11-2022 to date
See the board, name and registered office on a given date →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

Group and network

Connections & network

1 current director
Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

History

On 10 November 2022, PSYNAPSE was incorporated as a private limited company.1 DEMONT Camille Ange-Marie has served as director of the company since 2022.2 Total assets went from €109,061 in 2022 to €300,833 in 2025.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 16-11-2022
  3. 3National Bank, annual accounts 2022 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
30-09
NBB filing Annual accounts filed
financial year 2025 · abbreviated format · 61 days late
2025
27-08
NBB filing Annual accounts filed
financial year 2024 · full format · 27 days late
2024
31-12
Financial Liquidity more than 5 timescurrent ratio 21.98
Current ratio from 4.09 to 21.98; short-term debt falls from €46,432 to €13,600.
30-09
NBB filing Annual accounts filed
financial year 2023 · full format · 61 days late
2023
31-12
Financial Highest result from 2022 to 2025net €157,889 ▲142%
Operating result €206,014, net result €157,889, both a record.
31-12
Financial Liquidity more than 11 timescurrent ratio 4.09
Current ratio from 0.36 to 4.09.
31-12
Financial Equity above €200,000equity €225,057 ▲235%
A profit in every financial year since 2022 builds equity to €225,057.
17-08
NBB filing Annual accounts filed
financial year 2022 · full format · 17 days late
2022
16-11
Gazette deed Incorporation
Appointment: DEMONT Camille Ange-Marie (director) · Founder · Founding capital8 facts ▸
  • Founder, DEMONT Camille Ange-Marie
  • Incorporation, “PSYNAPSE” (deed in French)
  • Founding capital, €2,000
  • Capital
  • Registered office clause, “1330 Rixensart, rue de Nivelles”, 9 (deed in French)
  • Board rule, 1
  • Director appointment, DEMONT Camille Ange-Marie (director (not named in the articles))
  • Pre-incorporation commitments, “takeover, tous engagements ainsi que obligations qui en résultent et toutes activités entreprises par comparant au nom et pour compte de société en formation” (deed in French)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 1 deed read

Register details

Identification
Legal formPrivate limited company
Founded10-11-2022
Financial year end31-12
Activities, NACEBEL 2025
86220Specialist medical practice
E-invoicing
Reachable via Peppol
Peppol ID 0208:0793500778
Registered 27-01-2026

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Legal Entity Identifier

254900XW5Q5D99VFAY42
live in the LEI register

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Rixensart · 1 establishment unit since 2022
registered office establishment The establishment unit on the map
Ground area
2,067 m²
Building footprint
141 m²
Building volume
906 m³
Parcel 25091B0047/00_000, Wallonia · tallest building 8.8 m. Linked by address, not a title deed.
1 establishment unit
PSYNAPSE
Rue de Nivelles 9, 1330 RixensartSpecialist medical practice
since 2022unit no. 2.337.838.669
1 parcel
Wallonia 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
25091B0047/00_000 Wallonia 2,067 m² 1 · 141 m² 8.8 m · 2
How the parcels are linked
Good to know
The parcel matches the address exactly.

Articles of association

What the company does

DurationHow long the company exists; usually unlimited, so until it is dissolved.
Unlimited
Name clauseThe name the company operates under according to its articles.
PSYNAPSE
Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
“Région wallonne, transfert en tout endroit de la Région de Bruxelles-Capitale ou de la région de langue française de Belgique par simple…” (deed in French)

deed of 16-11-2022

Who represents it, and how

Board ruleHow the board is made up, meets and takes decisions.
“1, assemblée générale” (deed in French)
1 more provision on this in the deed

deed of 16-11-2022

Capital, shares and profit

Kind of sharesWhich classes of shares exist and what rights each class carries.
“Nominatives, usufruitier et nu-propriétaire inscrits séparément avec indication de leurs droits respectifs” (deed in French)
Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
“Prix offert candidat original, cession actions” (deed in French)

deed of 16-11-2022

Meetings and financial year

Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
Third Thursday of June at 18:00

deed of 16-11-2022

Oversight and winding up

Statutory auditorA statutory auditor is a registered auditor who checks the accounts; small companies need not have one. According to the deed, the legal criteria do not require one here.
No statutory auditor
Dissolution ruleWhen and by whom the company can be dissolved.
“Formes prévues pour les modifications aux statuts, assemblée générale” (deed in French)
Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
“Dissolution pour quelque cause et à quelque moment que ce soit, désigner un ou plusieurs liquidateurs et déterminer pouvoirs et émoluments” (deed in French)

deed of 16-11-2022

Other provisionsOther rules from the articles that fall under none of the themes above.

Other provision: “Appels de fonds, Les actions doivent être libérées à leur émission” (deed in French)
Other provision: “Exclusion et suspension, Toute décision d'exclusion est motivée” (deed in French)
Other provision: “Nature autres titres, registre titres nominatifs par catégorie” (deed in French)
Other provision: “Rémunération_des_administrateurs, fixe ou proportionnelle” (deed in French)
Other provision: “Agissent seuls, attributions_et_rémunérations_éventuelles” (deed in French)
Other provision: “Un ou plusieurs commissaires, Contrôle_de_la_société” (deed in French)
Other provision: “Assemblée_générale_par_procédure_écrite, membres organe commissaire titulaires obligations convertibles droits souscription certificats sur…” (deed in French)
Other provision: “Admission_à_l_assemblée_générale, inscrit_titres_nominatifs_registre_catégorie” (deed in French)
Other provision: “Séances_procès-verbaux, un_ou_plusieurs_membres_organe_ayant_représentation” (deed in French)
Other provision: “Toute_personne_actionnaire_ou_non_procuration_écrite_tout_moyen, Délibérations” (deed in French)
Other provision: “Toute assemblée générale ordinaire ou extraordinaire, prorogation de l'assemblée générale” (deed in French)
Other provision: “Répartition des bénéfices et réserves, assemblée générale” (deed in French)
Liquidation distribution: “Apurement dettes charges et frais de liquidation ou consignation montants nécessaires, après rétablissement égalité entre actions soit par…” (deed in French)
Other provision: “Préciser notamment mode de calcul des états de frais pour médecins et permettre rémunération normale du médecin pour travail presté…” (deed in French)
Other provision: “Exécution des statuts, toutes communications sommations assignations significations valablement faites” (deed in French)
Other provision: “Tout litige entre société actionnaires administrateurs commissaires et liquidateurs relatifs affaires société et exécution statuts…” (deed in French)
Other provision: “Droit commun, dispositions du Code des sociétés et des associations auxquelles il ne serait pas licitement dérogé réputées inscrites” (deed in French)
Other provision: “Toute modification aux statuts règlement d'ordre intérieur ou autre convention, autorisation préalable du conseil provincial de l'Ordre des…” (deed in French)
Other provision: “Conservation des dossiers médicaux en cas de cessation des activités, si pratique médicale ne fait pas objet d'une cession” (deed in French)
Other provision: “Déontologie médicale, société garantit à chaque médecin actionnaire exercice profession en toute indépendance dans respect secret médical…” (deed in French)
3 more provisions in the deed, see the deed of 16-11-2022

deed of 16-11-2022